8BN Optimi Health Corp

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to report a significant update to its collaboration with The Institute for Psychedelic Research at Tel Aviv University (IPR-TLV).

Optimi has obtained the Export Permit required from Health Canada for the shipment of its in-house manufactured MDMA active pharmaceutical ingredient (API) to IPR-TLV. With the Export Permit confirmed, Optimi will be one of the first psychedelics pharmaceutical manufacturers to ship MDMA to the country.

"Partnering with IPR-TLV and shipping MDMA to Israel marks a significant advancement for Optimi," said Bill Ciprick, CEO of Optimi Health. "As a supplier with the ability to produce GMP psychedelic pharmaceuticals on demand, we are proud to be furthering our mission of supporting psychedelic research and innovation on a global scale.”

In March, Optimi and IPR-TLV unveiled their collaboration, revealing that the MDMA API would support the institute's study on the impact of MDMA on alcohol addiction.

Optimi Health Chief Financial Officer, Jacob Safarik, commented, "Obtaining an Export Permit to ship controlled substances globally involves a meticulous process that demands collaboration from various stakeholders. We extend our gratitude to IPR-TLV and Health Canada for their partnership and cooperation in navigating this intricate procedure alongside our team at Optimi."

About MDMA-HCL

• Fully synthesized in-house at Optimi’s 10,000 sq ft cultivation and formulation facility in Princeton, British Columbia.
• Materials used to formulate MDMA-HCL were obtained through the Company’s Health Canada Precursor License.
• The material was tested internally and with third party analytical laboratories.
• The identity of the material has been confirmed through a variety of analytical techniques, including NMR spectroscopy, and assay testing which shows purity of the product of over 99%.
• The Company synthesized multiple batches of MDMA-HCL in multi-gram quantities to fulfill the order.

For media inquiries, please contact Michael Kydd:

michaelk@optimihealth.ca902.880.6121

For investor inquiries, please contact: investors@optimihealth.ca

www.optimihealth.ca

ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

Optimi Health Corp. is a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe drug candidates throughout the world. Optimi’s products are grown and manufactured at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia.

FORWARD‐LOOKING STATEMENTS

This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. forward-looking statements made in this news release include the proposed use of the proceeds of the Offering. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.